메뉴 건너뛰기




Volumn 18, Issue 4, 2013, Pages 233-236

Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: Report of four cases

Author keywords

Plasma exchange; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

ANTIHISTAMINIC AGENT; COTRIMOXAZOLE; ITRACONAZOLE; LACTATE DEHYDROGENASE; PARACETAMOL; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

EID: 84880027332     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000073     Document Type: Article
Times cited : (17)

References (18)
  • 1
    • 33646360865 scopus 로고    scopus 로고
    • Clinical practice. Thrombotic thrombocytopenic purpura
    • George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927-35.
    • (2006) N Engl J Med. , vol.354 , pp. 1927-1935
    • George, J.N.1
  • 2
    • 0032569884 scopus 로고    scopus 로고
    • von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome
    • Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. N Engl J Med. 1998;339:1578-84.
    • (1998) N Engl J Med. , vol.339 , pp. 1578-1584
    • Furlan, M.1    Robles, R.2    Galbusera, M.3    Remuzzi, G.4    Kyrle, P.A.5    Brenner, B.6
  • 3
    • 57749170320 scopus 로고    scopus 로고
    • TTP and ADAMTS-13. When is testing appropriate?
    • Pier MM, Flora P. TTP and ADAMTS-13. When is testing appropriate? Hematology. 2007;2007:121-6.
    • (2007) Hematology. , vol.2007 , pp. 121-126
    • Pier, M.M.1    Flora, P.2
  • 4
    • 78549253211 scopus 로고    scopus 로고
    • How I treat patients with thrombotic thrombocytopenic purpura: 2010
    • George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116:4060-9.
    • (2010) Blood. , vol.116 , pp. 4060-4069
    • George, J.N.1
  • 5
    • 33644795851 scopus 로고    scopus 로고
    • Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura
    • Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132:66-74.
    • (2006) Br J Haematol. , vol.132 , pp. 66-74
    • Coppo, P.1    Wolf, M.2    Veyradier, A.3    Bussel, A.4    Malot, S.5    Millot, G.A.6
  • 6
    • 33846018020 scopus 로고    scopus 로고
    • Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13
    • Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451-61.
    • (2007) Br J Haematol. , vol.136 , pp. 451-461
    • Scully, M.1    Cohen, H.2    Cavenagh, J.3    Benjamin, S.4    Starke, R.5    Killick, S.6
  • 7
    • 84055166960 scopus 로고    scopus 로고
    • Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with suboptimal response to plasma exchange
    • Froissart A, Buffet M, Veyradier A, Poullin Provot F, Malot S, Shwarzinger M, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with suboptimal response to plasma exchange. Crit Care Med. 2012;40:104-11.
    • (2012) Crit Care Med. , vol.40 , pp. 104-111
    • Froissart, A.1    Buffet, M.2    Veyradier, A.3    Poullin Provot, F.4    Malot, S.5    Shwarzinger, M.6
  • 8
    • 80051866867 scopus 로고    scopus 로고
    • A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
    • Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746-53.
    • (2011) Blood. , vol.118 , pp. 1746-1753
    • Scully, M.1    McDonald, V.2    Cavenagh, J.3    Hunt, B.J.4    Longair, I.5    Cohen, H.6
  • 9
    • 0037968640 scopus 로고    scopus 로고
    • ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients
    • Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-8.
    • (2003) Blood. , vol.102 , pp. 60-68
    • Vesely, S.K.1    George, J.N.2    Lammle, B.3    Studt, J.D.4    Alberio, L.5    El-Harake, M.A.6
  • 10
    • 47249144803 scopus 로고    scopus 로고
    • VonWillebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
    • Sadler JE. VonWillebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112:11-8.
    • (2008) Blood. , vol.112 , pp. 11-18
    • Sadler, J.E.1
  • 11
    • 77649205284 scopus 로고    scopus 로고
    • Successful long-term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura
    • Ojeda-Uribe M, Federici L, Wolf M, Coppo P, Veyradier A. Successful long-term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura. Transfusion. 2010;50:733-5.
    • (2010) Transfusion. , vol.50 , pp. 733-735
    • Ojeda-Uribe, M.1    Federici, L.2    Wolf, M.3    Coppo, P.4    Veyradier, A.5
  • 12
    • 77954397953 scopus 로고    scopus 로고
    • Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome
    • Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, Di Trapani R, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome. Blood Transfus. 2010; 8:203-10.
    • (2010) Blood Transfus. , vol.8 , pp. 203-210
    • Caramazza, D.1    Quintini, G.2    Abbene, I.3    Coco, L.L.4    Malato, A.5    Di Trapani, R.6
  • 13
    • 84868129528 scopus 로고    scopus 로고
    • Short-and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic pupura: Four case reports
    • Iioka F, Shimomura D, Ishii T, Maesako Y, Ohgoe K, Nakamura F, et al. Short-and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic pupura: four case reports. Int J Hematol. 2012;96:506-12.
    • (2012) Int J Hematol. , vol.96 , pp. 506-512
    • Iioka, F.1    Shimomura, D.2    Ishii, T.3    Maesako, Y.4    Ohgoe, K.5    Nakamura, F.6
  • 16
    • 78751580375 scopus 로고    scopus 로고
    • Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia
    • Li Z, Mou W, Lu G, Cao J, He X, Pan X, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93:91-8.
    • (2011) Int J Hematol. , vol.93 , pp. 91-98
    • Li, Z.1    Mou, W.2    Lu, G.3    Cao, J.4    He, X.5    Pan, X.6
  • 17
    • 84860350202 scopus 로고    scopus 로고
    • Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: Clinical efficacy and biologic studies
    • Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119:3691-7.
    • (2012) Blood. , vol.119 , pp. 3691-3697
    • Barcellini, W.1    Zaja, F.2    Zaninoni, A.3    Imperiali, F.G.4    Battista, M.L.5    Di Bona, E.6
  • 18
    • 79955044153 scopus 로고    scopus 로고
    • Human immunodeficiency virus associated thrombotic thrombocytopenic purpura-favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy
    • Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura-favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011;153:515-9.
    • (2011) Br J Haematol. , vol.153 , pp. 515-519
    • Hart, D.1    Sayer, R.2    Miller, R.3    Edwards, S.4    Kelly, A.5    Baglin, T.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.